Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1768527 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL1768587 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL1768585 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL1768548 | 0.91 | SMN1; SMN2 (0.61) | SMN1; SMN2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL1768546 | 0.91 | SMN1; SMN2 (0.61) | SMN1; SMN2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL1768556 | 0.89 | SMN1; SMN2 (0.44) | SMN1; SMN2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL1768552 | 0.89 | SMN1; SMN2 (0.44) | SMN1; SMN2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL10132091 | 0.85 | LMNA (0.56) | SMN1; SMN2BLMKMT2AALDH1A1LMNA | |
| SCHEMBL25357691 | 0.84 | GSR (0.46) | SMN1; SMN2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL25357686 | 0.84 | GSR (0.46) | SMN1; SMN2GRM8GRM6GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528808-B2 | Therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-01-20 | — | — | US | disclosed |
| US-20220249473-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-08-11 | — | — | US | disclosed |
| CN-114096250-A | Novel therapy for erythropoietic protoporphyrinopathy (EPP) and X-linked protoporphyrinopathy (XLP) | 匹兹堡大学联邦高等教育系统 | 2022-02-25 | — | — | CN | disclosed |
| WO-2020236901-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-11-26 | — | — | WO | disclosed |
| CN-102712676-B | There is the peptidomimetic that the template of CCR10 antagonistic activity is fixing | 波利弗尔股份公司 | 2016-10-26 | — | — | CN | disclosed |
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| CN-102712676-A | Template-fixed peptidomimetics with CCR10 antagonistic activty | POLYPHOR AG | 2012-10-03 | — | — | CN | disclosed |
| EP-2501715-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | Polyphor Ag (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011060937-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528808-B2 | Therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) | ABCC3, ABCC2, ABCB7 | SMN1; SMN2 4747/4885GRM8 4618/4885GRM6 2857/4885 |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | SMN1; SMN2 1981/4885GRM8 1650/4885GRM6 1857/4885 |
| US-20220249473-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | XPA, TPX2, XPOT | SMN1; SMN2 4778/4885GRM8 4791/4885GRM6 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.